Skip to content
prognosis

Novavax Covid Shot Highly Effective Versus Variants in Trial

Updated on
  • Vaccine prevents moderate and severe symptoms in phase 3 study
  • First doses largely going to low-, moderate-income countries
WATCH: The Novavax CEO talks about the efficacy of its Covid shot.

Novavax Inc.’s Covid-19 vaccine candidate showed strong efficacy against the coronavirus in a large trial that signals a new option is nearing for a global community still desperate for protection against the virus and its variants.

The shot was 90% effective at preventing symptomatic Covid and 100% effective at preventing moderate and severe symptoms, the U.S.-based biotech firm said in a statement on Monday. It was also 93% effective against variants of concern, according to results from a secondary analysis that mostly included cases of the alpha variant predominant in the U.S.